Newsletter | December 16, 2025
TOP EDITORIAL
1.
From Scientific Discovery To Next Generation Treatments For Obesity
2.
Epic Bio's Big Swing In Epigenetic Editing
3.
Partnering To Commercialize Radiopharmaceuticals
4.
The Death Of A Dogma: David Baltimore And Lessons For Modern Drug Discovery
5.
Reading The FDA Tea Leaves On Psychedelics
TOP 10 GUEST COLUMNS
Why So Many Biotech Launches Miss Expectations, And How To Fix It
By Bennett Smith
IP Law: In Defense Of Polymorphs
By James T. Masters & Eric J. Fues
Life Sciences 2025 2H Trends: Regulations, Precision Medicine, Oncology Investment
By Kristin Pothier and Amy Matsuo
Early-Stage Life Sciences Partnerships Raise Later-Stage Considerations
By Adam Welland, Meena Datta, Mathew Eapen, and Torrey Cope
The Future Of Psychedelic-Inspired Therapeutics: No-Trip Neuroplastogens
By Joseph Tucker, Ph.D.
6.
Balanced Disruption: Leading Change In A Family-Owned Pharma Company
By Stefan König
7.
What Life Sciences Companies Can Learn From BMW and Volkswagen
By Noël Theodosiou and Patrick O. Gee
8.
Helping Quiet Life Science Leaders Be Seen, Heard, And Valued
By Joel Garfinkle
9.
Why I Love Working With Leaders Who Have 'Rounded Corners'
By Tara Miller
10.
Pharma Direct-To-Patient 2.0: From Experiment To Imperative
By Deepak Thomas and Sari Kaganoff
TOP 10 INDUSTRY INSIGHTS
What Does 2025 Hold For Pharma?
By Darcy Grabenstein, Citeline
Assessing E&Ls From Single-Use Systems Used In ATMP Production
By Sartorius
North Carolina Life Sciences Growth Outpaces Nation
By Chris Capot, NCBiotech
Thunderstruck By Antibody-Drug Conjugates
By Cytiva
Agentic AI And How It's Impacting Clinical Trial Research
By Medable
Navigating The Potential Of Generative AI In Life Sciences
By Ray Beste, Sikich
Why Patient Optionality Is The Key To Advancing Clinical Research
By EmVenio Clinical Research
The Changing Vaccine Development Landscape
By FUJIFILM Biotechnologies
Key Updates To Implementing Regulation (EU) 520/2012
By Ergomed Clinical Research
Digging Through The Hype: Can AI/ML Assist Clinical Development?
By Revvity Signals Software, Inc.
